Mytocel MSK / Rigenera
Auricular cartilage biopsy; mechanical disaggregation only. No culture, enzyme digestion or ex-vivo expansion. Prepared during the clinical sitting.
For medical professionals
A cartilage operation, redesigned as a needle-delivered protocol.
NanoACi is a surgeon-led, point-of-care technique combining mechanically prepared autologous cartilage micrografts, a cell-free collagen matrix and autologous PRP before intra-articular needle delivery in one sitting.
Register professional interestWorking definition
Protocol—not a new manufactured product.
The intellectual value sits in patient selection, preparation sequence, ratios, timing, delivery and post-procedure care—the reproducible technique as a whole.
NANon-Arthroscopic
No arthroscopic access is used for delivery.
NNeedle-Delivered
Image-guided delivery by an appropriately trained surgeon.
OOne-Stage
Harvest, preparation, combination and delivery in one sitting.
ACAutologous Chondrogenic
Autologous tissue selected for a cartilage-supporting biological intent.
iinjection
The lower-case “i” distinguishes injection from conventional implantation.
Technique architecture
Cells. Matrix. Signal.
Separate components, brought together at point of care under a defined surgical protocol.
ChondroFiller® liquid
Cell-free native type I collagen matrix supplied in a two-chamber syringe, forming a hydrogel after component mixing.
Platelet-rich plasma
Patient-derived platelet-rich plasma, a platelet concentrate carrying growth factors, prepared from a standard blood draw.
Same patientSame sittingNo storageNo culture
Scientific position
Published component research. NanoACi 100 clinical findings.
Published studies of autologous cartilage micrografts report improvements in pain and knee function. Collagen scaffold research examines cartilage repair in treated defects, while PRP studies assess pain and functional outcomes. These distinct biological roles inform the NanoACi approach.
Explore the study populations, treatments and reported findings in our evidence library, alongside the clinical update from Professor Paul Lee on NanoACi 100.
Review the evidence map100
Clinical outcomes
NanoACi 100: treatment phase complete, early findings encouraging.
The treatment phase of NanoACi 100 is complete and the series is now in its observation stage. Professor Paul Lee reports encouraging early findings, with a four-point reduction in pain on the 0–10 visual analogue scale (VAS) at six-week follow-up. Analysis and follow-up are ongoing.
Treatment phase complete Observation stageContinuing follow-upSix-week pain assessment
Diagnosis, grade, imaging, prior treatment and patient goals.
Joint, preparation variables, delivery details and protocol deviations.
Pain, function, quality of life, satisfaction, return to activity and safety.
Consistent follow-up milestones, with longer-term data continuing beyond publication.
Build the network
Refer. Observe. Research. Learn.
Professional interest is open to surgeons, sports physicians, radiologists, physiotherapists and research collaborators who want to follow the evidence or explore future training.
Join the professional list